Ajanta Pharma Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Ajanta Pharma’s Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Ajanta Pharma Q3 Results 2026 Preview

• Ajanta Pharma’s revenue is expected to be in the range of ₹1,146.13 crore, a 3.41% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 7.58% YoY. 
• Ajanta Pharma’s EBITDA is expected to fall to ₹284.86 crore. 
• Net profit is ₹232.88 crore, a rise 7.58% YoY 

Ajanta Pharma Share Performance 

• Over the past six months, Ajanta Pharma’s share price has fallen by 4.31% to ₹2,701.50.
• Moreover, over the past year, the stock has increased by 2.83%.
• Despite this weak short-term performance, Ajanta Pharma’s stock has delivered a financially sound 129.72% return over the past 5 years.
• As of 29th January 2026, the stock traded at ₹2,707.10 per share.

Key Factors to Watch for Ajanta Pharma Q3 Results FY26 

• Revenue growth across segments – Trend in sales, especially branded generics performance in India, Asia and Africa, and US generics contribution.
• Profitability and margins – Movement in EBITDA and net profit margins amid cost pressures and forex impacts.
• Domestic branded generics momentum vs market – How India branded growth compares with overall Indian Pharmaceutical Market (IPM).
• Cost management – Trends in employee, R&D and other operating expenses that influence bottom-line quality.
• International expansion & strategic actions – Updates on global expansion (e.g., new subsidiary in Ireland) and product launches or regulatory approvals. 

Final Thoughts

Ajanta Pharma will announce its Q3 FY26 results on 30th January 2026. Analysts expect 3.41% YoY revenue growth, a 7.58% rise in PAT, and a 5.81% fall in EBITDA. Ajanta Pharma focuses on branded generics growth across India, Asia and Africa, US generics performance, margins amid cost pressures, ANDA approvals/new launches, and geographic/therapy diversification efforts.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here